Cited by 1,124Diabetes Treatment and ManagementPeptidase Inhibition and AnalysisPancreatic function and diabetes

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

Kieffer, T J, McIntosh, C H, Pederson, R A·1995·Endocrinology

Open this paper in CoChat — free account

Abstract

The combined actions of glucose-dependent insulinotropic polypeptide (GIP) and truncated glucagon-like peptide-1 (tGLP-1) may fully account for the incretin effect. These hormones are released from the small intestine in response to oral glucose and stimulate insulin release. Recently, evidence has been provided demonstrating the degradation of GIP-(1-42) and GLP-1-(7-36)NH2 by the serum enzyme dipeptidyl peptidase IV (DPP IV) into the biologically inactive products GIP-(3-42) and GLP-1-(9-36)NH2. The objective of the current investigation was to develop a method to monitor the degradation of these hormones in vivo. Synthetic peptides were radiolabeled and purified by HPLC. Subsequent degradation of the peptides under various conditions was then monitored by further HPLC analysis. Incubation of [125I]GIP-(1-42) or [125I]GLP-1-(7-36)NH2 with Wistar rat serum or purified DPP IV resulted in the major N-terminal-truncated products [125I]GIP-(3-42) and [125I]GLP-1-(9-36)NH2. These products were significantly reduced when the specific DPP IV inhibitor diprotin A was included in the incubation mixture and were absent when serum from DPP IV-deficient rats was used. When the labeled peptides were infused into rats at hormone levels within the physiological range, over 50% was metabolized to the truncated forms within 2 min. These products were absent when the tracers were infused into DPP IV-deficient animals. It is concluded that DPP IV may be a primary inactivating enzyme of both GIP and tGLP-1 in vivo. As the N-terminal-truncated products of the DPP IV cleavage may not be distinguished from the biologically active hormone by currently employed assays, reports of circulating hormone levels should be reconsidered. The method described in this manuscript may be useful for investigating the durations of action of GIP and tGLP-1 in normal and pathophysiological conditions.

Integrity signals

Registry

Crossref · 10.1210/endo.136.8.7628397

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing
Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Hamster preproglucagon contains the sequence of glucagon and two related peptides
Bell, G. I., Santerre, R. F., & Mullenbach, G. T. (1983) · Nature · doi:10.1038/302716a0 · Cited by 649
Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)
Holz, G. G., Kiihtreiber, W. M., & Habener, J. F. (1993) · Nature · doi:10.1038/361362a0 · Cited by 591
Proline-Dependent Structural and Biological Properties of Peptides and Proteins
Yaron, A., Naider, F. R., & Scharpé, S. (1993) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409239309082572 · Cited by 551
A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-?-naphthylamide
Hopsu-Havu, V. K., & Glenner, G. G. (1966) · Histochemistry and Cell Biology · doi:10.1007/bf00577838 · Cited by 437
Entero-Insular Axis
Unger, R. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130043007 · Cited by 371

Show all 36 references

Sorted by citations

Items 401–500 of 997

Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide
O'Harte, F. P. M., Mooney, M., Kelly, C. M., & Flatt, P. R. (2000) · Journal of Endocrinology · doi:10.1677/joe.0.1650639 · Cited by 50
Glucagon‐like peptide‐1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?
Borner, T., Tinsley, I. C., Doyle, R. P., Hayes, M. R., & Jonghe, B. C. D. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15647 · Cited by 48
Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in association with its effects suppressing endoplasmic reticulum stress in db/db mice
Wu, Y., Guo, X., Li, C., Li, D., Zhang, J., Yang, Y., Kong, Y., Guo, H., Liu, D., & Chen, L. (2014) · Metabolism · doi:10.1016/j.metabol.2014.08.006 · Cited by 50
Gut Hormones: A Weight Off Your Mind
Gardiner, J., Jayasena, C. N., & Bloom, S. R. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01729.x · Cited by 49
Combined Oral Administration of GABA and DPP-4 Inhibitor Prevents Beta Cell Damage and Promotes Beta Cell Regeneration in Mice
Liu, W., Son, D. O., Lau, H., Zhou, Y., Prud’homme, G. J., Jin, T., & Wang, Q. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00362 · Cited by 50
Impact of Sitagliptin on Endometrial Mesenchymal Stem-Like Progenitor Cells: A Randomised, Double-Blind Placebo-Controlled Feasibility Trial
Tewary, S., Lucas, E. S., Fujihara, R., Kimani, P., Polanco, A., Brighton, P. J., Muter, J., Fishwick, K. J., Diniz-da-Costa, M., Ewington, L. J., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.102597 · Cited by 48
Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid
Green, B., Gault, V. A., Flatt, P. R., Harriott, P., Greer, B., & O'Harte, F. P. M. (2004) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2004.05.005 · Cited by 50
New treatments in type 2 diabetes: a focus on the incretin‐based therapies
Barnett, A. H. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03396.x · Cited by 50
Incretin Mimetics and DPP-IV Inhibitors: New Paradigms for the Treatment of Type 2 Diabetes
Hinnen, D., Nielsen, L. L., Waninger, A., & Kushner, P. (2006) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.19.6.612 · Cited by 48
Dipeptidyl‐Peptidase IV‐β, a Novel form of Cell‐Surface‐Expressed Protein with Dipeptidyl‐Peptidase IV Activity
Jacotot, E. D., Callebaut, C., Blanco, J., Krust, B., Neubert, K., Barth, A., & Hovanessian, A. G. (1996) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1996.0248u.x · Cited by 49
The enteroinsular axis in dipeptidyl peptidase IV-negative rats
Pederson, R. A., Kieffer, T. J., Pauly, R. P., Kofod, H., Kwong, J., & McIntosh, C. H. S. (1996) · Metabolism · doi:10.1016/s0026-0495(96)90112-2 · Cited by 49
Self-citation
Nutrition and l and K-enteroendocrine cells
Gutierrez-Aguilar, R., & Woods, S. C. (2011) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32834190b5 · Cited by 47
Exendin-4 Prevents Vascular Smooth Muscle Cell Proliferation and Migration by Angiotensin II via the Inhibition of ERK1/2 and JNK Signaling Pathways
Nagayama, K., Kyotani, Y., Zhao, J., Ito, S., Ozawa, K., Bolstad, F., & Yoshizumi, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137960 · Cited by 48
Production of a novel wheat gluten hydrolysate containing dipeptidyl peptidase-IV inhibitory tripeptides using ginger protease
Taga, Y., Hayashida, O., Kusubata, M., Ogawa‐Goto, K., & Hattori, S. (2017) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2017.1345615 · Cited by 48
Critical Role of Dipeptidyl Peptidase IV: A Therapeutic Target for Diabetes and Cancer
De, S., Banerjee, S., Kumar, S. K. A., & Paira, P. (2018) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557518666180423112154 · Cited by 48
Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db / db mice
Joseph, J. W., Kalitsky, J., St-Pierre, S. A., & Brubaker, P. L. (2000) · Diabetologia · doi:10.1007/s001250051529 · Cited by 48
Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment
Neumiller, J. J. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.024 · Cited by 47
Novel Biological Action of the Dipeptidylpeptidase-IV Inhibitor, Sitagliptin, as a Glucagon-Like Peptide-1 Secretagogue
Sangle, G. V., Lauffer, L. M., Grieco, A. J., Trivedi, S., Iakoubov, R., & Brubaker, P. L. (2011) · Endocrinology · doi:10.1210/en.2011-1732 · Cited by 47
Beneficial effects of a N-terminally modified GIP agonist on tissue-level bone material properties
Mabilleau, G., Mieczkowska, A., Irwin, N., Simon, Y., Audran, M., Flatt, P. R., & Chappard, D. (2014) · Bone · doi:10.1016/j.bone.2014.02.013 · Cited by 47
Improvement of blood glucose levels and obesity in mice given aronia juice by inhibition of dipeptidyl peptidase IV and α-glucosidase
Yamane, T., Kozuka, M., Konda, D., Nakano, Y., Nakagaki, T., Ohkubo, I., & Ariga, H. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.02.004 · Cited by 50
Therapeutic Potential of Peptides Derived from Animal Venoms: Current Views and Emerging Drugs for Diabetes
Coulter‐Parkhill, A., McClean, S., Gault, V. A., & Irwin, N. (2021) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514211006071 · Cited by 50
Recent Advances in Antidiabetic Drug Therapies Targeting the Enteroinsular Axis
Flatt, P. R., Bailey, C. J., & Green, B. (2009) · Current Drug Metabolism · doi:10.2174/138920009787522124 · Cited by 46
Dipeptidyl peptidase-4 expression is reduced in Crohn's disease
Moran, G. W., O’Neill, C. A., Padfield, P. J., & McLaughlin, J. T. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2012.04.006 · Cited by 46
Vildagliptin Ameliorates Oxidative Stress and Pancreatic Beta Cell Destruction in Type 1 Diabetic Rats
Ávila, D. L., de Araújo, G. R., Silva, M., Miranda, P. H. D. A., Diniz, M. F., Pedrosa, M. L., Silva, M. E., de Lima, W. G., & Costa, D. C. (2013) · Archives of Medical Research · doi:10.1016/j.arcmed.2013.03.004 · Cited by 46
Pathophysiology of diabetes mellitus type 2: beyond the duo "insulin resistance-secretion deficit".
Boada, C. A. C., & Martínez-Moreno, J. M. (2013) · PubMed · doi:10.3305/nh.2013.28.sup2.6717 · Cited by 44
Restoration of Cerebral and Systemic Microvascular Architecture in APP / PS 1 Transgenic Mice Following Treatment with Liraglutide™
Kelly, P., McClean, P. L., Ackermann, M., Konerding, M. A., Hölscher, C., & Mitchell, C. A. (2014) · Microcirculation · doi:10.1111/micc.12186 · Cited by 48
Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes
Claus, T. H., Pan, C. Q., Buxton, J. M., Yang, L., Reynolds, J. C., Barucci, N., Burns, M. G., Ortiz, A. A., Roczniak, S., Livingston, J. N., et al. (2007) · Journal of Endocrinology · doi:10.1677/joe-06-0018 · Cited by 46
Gastro-intestinal hormones GIP and GLP-1
Kieffer, T. J. (2004) · Annales d Endocrinologie · doi:10.1016/s0003-4266(04)95625-9 · Cited by 46
Self-citation
Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels
Johnson, K., Edgerton, D. S., Rodewald, T., Scott, M. F., Farmer, B., Neal, D. W., & Cherrington, A. D. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00275.2007 · Cited by 46
Racial differences in glucagon-like peptide-1 (GLP-1) concentrations and insulin dynamics during oral glucose tolerance test in obese subjects
Velasquez‐Mieyer, P., Cowan, P. A., Umpierrez, G. E., Lustig, R. H., Cashion, A. K., & Burghen, G. A. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802415 · Cited by 46
Lesions of area postrema and subfornical organ alter exendin-4-induced brain activation without preventing the hypophagic effect of the GLP-1 receptor agonist
Baraboi, E., Smith, P., Ferguson, A. V., & Richard, D. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00326.2009 · Cited by 44
Transplantable rat glucagonomas cause acute onset of severe anorexia and adipsia despite highly elevated NPY mRNA levels in the hypothalamic arcuate nucleus.
Jensen, P. B., Blume, N., Mikkelsen, J. D., Larsen, P. J., Jensen, H. I., Holst, J. J., & Madsen, O. D. (1998) · Journal of Clinical Investigation · doi:10.1172/jci275 · Cited by 45
Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
Choe, H. J., & Cho, Y. M. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.102 · Cited by 48
Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
Cho, Y. M., Wideman, R. D., & Kieffer, T. J. (2013) · Endocrinology and Metabolism · doi:10.3803/enm.2013.28.4.262 · Cited by 47
Self-citation
Sitagliptin: a review
SUBBARAYAN, S. K., & Kipnes, M. S. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.580738 · Cited by 46
Variant fatty acid-like molecules Conjugation, novel approaches for extending the stability of therapeutic peptides
Li, Y., Wang, Y., Wei, Q., Zheng, X., Tang, L., Kong, D., & Gong, M. (2015) · Scientific Reports · doi:10.1038/srep18039 · Cited by 45
Incretin Mimetics and Dipeptidyl Peptidase-IV Inhibitors: A Review of Emerging Therapies for Type 2 Diabetes
Kendall, D. M., Kim, D. S., & Maggs, D. G. (2006) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.8.385 · Cited by 44
Exendin-4 treatment improves metabolic control after rat islet transplantation to athymic mice with streptozotocin-induced diabetes
Sharma, A., Sörenby, A. K., Wernerson, A. M., Efendić, S., Kumagai‐Braesch, M., & Tibell, A. (2006) · Diabetologia · doi:10.1007/s00125-006-0251-2 · Cited by 45
Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: A new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554
Banno, Y., Miyamoto, Y., Sasaki, M., Oi, S., Asakawa, T., Kataoka, O., Takeuchi, K., Suzuki, N., Ikedo, K., Kosaka, T., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.06.059 · Cited by 44
Dipeptidyl Peptidase IV Is a Human and Murine Neutrophil Chemorepellent
Herlihy, S. E., Pilling, D., Maharjan, A. S., & Gomer, R. H. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202583 · Cited by 43
Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
Sebastián-Martín, A., Sánchez, B. G., Mora-Rodríguez, J. M., Bort, A., & Díaz‐Laviada, I. (2022) · Biomedicines · doi:10.3390/biomedicines10082026 · Cited by 48
Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties
Kerr, B. D., Irwin, N., O'Harte, F. P. M., Bailey, C. J., Flatt, P. R., & Gault, V. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.037 · Cited by 44
N-terminally modified glucagon-like peptide-1(7–36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo
O'Harte, F. P. M. (2000) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(99)00214-7 · Cited by 44
An update on the islet renin–angiotensin system
Cheng, Q., & Leung, P. S. (2011) · Peptides · doi:10.1016/j.peptides.2011.03.003 · Cited by 43
Exendin-4 promotes the vascular smooth muscle cell re-differentiation through AMPK/SIRT1/FOXO3a signaling pathways
Liu, Z., Zhang, M., Zhou, T., Shen, Q., & Qin, X. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.07.016 · Cited by 43
The endocrine pancreas in non‐diabetic rats after short‐term and long‐term treatment with the long‐acting GLP‐1 derivative NN2211
Bock, T. G., Pakkenberg, B., & Buschard, K. (2003) · Apmis · doi:10.1111/j.1600-0463.2003.apm1111207.x · Cited by 43
Development of Radiotracers for the Determination of the Beta-Cell Mass In Vivo
Brom, M., Andraojc, K., Oyen, W. J. G., Boerman, O. C., & Gotthardt, M. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791164126 · Cited by 42
Protein Engineering Strategies for Sustained Glucagon-Like Peptide-1 Receptor–Dependent Control of Glucose Homeostasis
Picha, K. M., Cunningham, M. R., Drucker, D. J., Mathur, A. S., Ort, T., Scully, M. S., Soderman, A. R., Spinka-Doms, T., Stojanovic-Susulic, V., Thomas, B. A., et al. (2008) · Diabetes · doi:10.2337/db07-1775 · Cited by 41
Response of plasma glucagon-like peptide-2 to feeding pattern and intraruminal administration of volatile fatty acids in sheep
Elsabagh, M., Inabu, Y., Obitsu, T., & Sugino, T. (2017) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2017.03.001 · Cited by 44
Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues
Green, B. D., Gault, V. A., Mooney, M. H., Irwin, N., Harriott, P., Greer, B., Bailey, C. J., O'Harte, F. P. M., & Flatt, P. R. (2004) · Biological Chemistry · doi:10.1515/bc.2004.035 · Cited by 42
Identification and characterization of a dipeptidyl peptidase IV inhibitor from aronia juice
Kozuka, M., Yamane, T., Nakano, Y., Nakagaki, T., Ohkubo, I., & Ariga, H. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.08.031 · Cited by 41
Endogenous GLP-1 as a key self-defense molecule against lipotoxicity in pancreatic islets
HUANG, C., YUAN, L., & CAO, S. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2207 · Cited by 41
Elimination and Degradation of Glucagon-like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Patients with End-Stage Renal Disease
Idorn, T., Knop, F. K., Jørgensen, M. B., Christensen, M., Holst, J. J., Hornum, M., & Feldt‐Rasmussen, B. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3809 · Cited by 41
3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: A class of potent DPP-4 inhibitors
Eckhardt, M., Hauel, N. H., Himmelsbach, F., Langkopf, E., Nar, H., Mark, M., Tadayyon, M., Thomas, L. H., Guth, B. D., & Lotz, R. R. H. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.04.075 · Cited by 41
Combination Therapy with a Dipeptidyl Peptidase-4 Inhibitor and a Proton Pump Inhibitor Induces β-Cell Neogenesis from Adult Human Pancreatic Duct Cells Implanted in Immunodeficient Mice
Suarez‐Pinzon, W. L., & Rabinovitch, A. (2011) · Cell Transplantation · doi:10.3727/096368910x557263 · Cited by 41
Ability of GLP-1 to decrease food intake is dependent on nutritional status
Ronveaux, C. C., de Lartigue, G., & Raybould, H. E. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.06.015 · Cited by 44
The positive charge at Lys‐288 of the glucagon‐like peptide‐1 (GLP‐1) receptor is important for binding the N‐terminus of peptide agonists
Al‐Sabah, S., & Donnelly, D. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)01043-3 · Cited by 41
Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37)
Irwin, N., Gault, V. A., Green, B. D., Greer, B., Harriott, P., Bailey, C. J., Flatt, P. R., & O'Harte, F. P. M. (2005) · Biological Chemistry · doi:10.1515/bc.2005.079 · Cited by 41
Free fatty acids administered into the colon promote the secretion of glucagon-like peptide-1 and insulin
Adachi, T., Tanaka, T., Takemoto, K., Koshimizu, T., Hirasawa, A., & Tsujimoto, G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.11.162 · Cited by 41
Degradation, Insulin Secretion, and Antihyperglycemic Actions of Two Palmitate-DerivitizedN-Terminal Pyroglutamyl Analogues of Glucose-Dependent Insulinotropic Polypeptide
Irwin, N., Green, B. D., Gault, V. A., Greer, B., Harriott, P., Bailey, C. J., Flatt, P. R., & O'Harte, F. P. M. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049262s · Cited by 41
Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors
Ikuma, Y., Hochigai, H., Kimura, H., Nunami, N., Kobayashi, T., Uchiyama, K., Furuta, Y., Sakai, M., Horiguchi, M., Masui, Y., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.07.046 · Cited by 40
A review of exenatide as adjunctive therapy in patients with type 2 diabetes
Robles, G. I. (2009) · Drug Design Development and Therapy · doi:10.2147/dddt.s3321 · Cited by 41
The incretin effect in K orean subjects with normal glucose tolerance or type 2 diabetes
Oh, T. J., Kim, M. Y., Shin, J. Y., Lee, J. C., Kim, S., Park, K. S., & Cho, Y. M. (2013) · Clinical Endocrinology · doi:10.1111/cen.12167 · Cited by 41
Non-invasive Beta-cell Imaging: Visualization, Quantification, and Beyond
Murakami, T., Fujimoto, H., & Inagaki, N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.714348 · Cited by 32
Differential regional metabolism of glucagon in anesthetized pigs
Deacon, C. F., Kelstrup, M., Trebbien, R., Klarskov, L., Olesen, M., & Holst, J. J. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00125.2003 · Cited by 40
Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide
Irwin, N., Clarke, G. C., Green, B. D., Greer, B., Harriott, P., Gault, V. A., O'Harte, F. P. M., & Flatt, P. R. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.06.013 · Cited by 40
Synthesis and evaluation of pyrazolidine derivatives as dipeptidyl peptidase IV (DP-IV) inhibitors
Ahn, J. H., Kim, J. A., Kim, H.-M., Kwon, H.-M., Huh, S.-C., Rhee, S. D., Kim, K. R., Yang, S., Park, S.-D., Lee, J., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.01.020 · Cited by 40
Sustained Expression of Exendin-4 Does Not Perturb Glucose Homeostasis, β-Cell Mass, or Food Intake in Metallothionein-Preproexendin Transgenic Mice
Baggio, L. L., Adatia, F. A., Bock, T. G., Brubaker, P. L., & Drucker, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005119200 · Cited by 41
Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
Miñambres, I., & Pérez, A. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0204-6 · Cited by 39
Cardiovascular effects of GLP‐1 and GLP‐1‐based therapies: implications for the cardiovascular continuum in diabetes?
Burgmaier, M., Heinrich, C., & Marx, N. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03746.x · Cited by 39
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 42
Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes
Gault, V. A., Flatt, P. R., Bailey, C. J., Harriott, P., Greer, B., Mooney, M. H., & O'Harte, F. P. M. (2002) · Biochemical Journal · doi:10.1042/bj20020319 · Cited by 38
Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit
Backes, B. J., Longenecker, K. L., Hamilton, G. L., Stewart, K. D., Lai, C., Kopecka, H., von Geldern, T. W., Madar, D. J., Pei, Z., Lubben, T. H., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.01.026 · Cited by 39
Fused bicyclic heteroarylpiperazine-substituted l-prolylthiazolidines as highly potent DPP-4 inhibitors lacking the electrophilic nitrile group
Yoshida, T., Akahoshi, F., Sakashita, H., Sonda, S., Takeuchi, M., Tanaka, Y., Nabeno, M., Kishida, H., Miyaguchi, I., & Hayashi, Y. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.06.033 · Cited by 39
MLR-1023 Is a Potent and Selective Allosteric Activator of Lyn Kinase In Vitro That Improves Glucose Tolerance In Vivo
Saporito, M. S., Ochman, A. R., Lipinski, C. A., Handler, J. A., & Reaume, A. G. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.192096 · Cited by 39
Formulary Forum: Exenatide: A New Option for the Treatment of Type 2 Diabetes
Yoo, B. K., Triller, D. M., & Yoo, D. J. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h060 · Cited by 39
Brain access of incretins and incretin receptor agonists to their central targets relevant for appetite suppression and weight loss
Buller, S., & Blouet, C. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00250.2023 · Cited by 40
The Dipeptidyl Peptidases 4, 8, and 9 in Mouse Monocytes and Macrophages: DPP8/9 Inhibition Attenuates M1 Macrophage Activation in Mice
Waumans, Y., Vliegen, G., Maes, L., Rombouts, M., Declerck, K., der Veken, P. V., Berghe, W. V., Meyer, G. R. Y. D., Schrijvers, D. M., & Meester, I. D. (2015) · Inflammation · doi:10.1007/s10753-015-0263-5 · Cited by 39
Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents
Li, G., Huan, Y., Yuan, B., Wang, J., Jiang, Q., Lin, Z., Shen, Z., & Huang, H. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.08.023 · Cited by 38
Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer’s disease pathology
Tramutola, A., Arena, A., Cini, C., Butterfield, D. A., & Barone, E. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1246183 · Cited by 40
Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects
Yanagimachi, T., Fujita, Y., Takeda, Y., Honjo, J., Sakagami, H., Kitsunai, H., Takiyama, Y., Abiko, A., Makino, Y., Kieffer, T. J., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2016.12.009 · Cited by 39
Self-citation
What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands
Elmansi, A. M., Awad, M. E., Eisa, N. H., Kondrikov, D., Hussein, K. A., Aguilar‐Perez, A., Herberg, S., Periyasamy‐Thandavan, S., Fulzele, S., Hamrick, M. W., et al. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.005 · Cited by 38
The major glucagon-like peptide-1 metabolite, GLP-1-(9–36)-amide, does not affect glucose or insulin levels in mice
Rolin, B., Deacon, C. F., Carr, R. D., & Åhrén, B. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.05.013 · Cited by 37
Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors
Qiao, L., Baumann, C. A., Crysler, C. S., Ninan, N. S., Abad, M. C., Spurlino, J. C., DesJarlais, R. L., Kervinen, J., Neeper, M. P., Bayoumy, S. S., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.09.037 · Cited by 38
Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide
Gault, V. A., Flatt, P. R., Harriott, P., Mooney, M., Bailey, C. J., & O'Harte, F. P. M. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1760133 · Cited by 38
Effect of Lipidation on the Structure, Oligomerization, and Aggregation of Glucagon-like Peptide 1
Brichtová, E. P., Edu, I. A., Li, X., Becher, F. J., dos Santos, A. L. G., & Jackson, S. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00484 · Cited by 38
Simultaneous determination of incretin hormones and their truncated forms from human plasma by immunoprecipitation and liquid chromatography–mass spectrometry
WOLF, R., Hoffmann, T., Rosche, F., & Demuth, H. (2004) · Journal of Chromatography B · doi:10.1016/j.jchromb.2003.11.044 · Cited by 37
High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats
Mul, J. D., Begg, D. P., Barrera, J. G., Li, B., Matter, E. K., D’Alessio, D. A., Woods, S. C., Seeley, R. J., & Sandoval, D. A. (2013) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00588.2012 · Cited by 38
Elevated basal and post-feed glucagon-like peptide 1 (GLP-1) concentrations in the neonatal period
Padidela, R., Patterson, M., Sharief, N., Ghatei, M. A., & Hussain, K. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0807 · Cited by 37
Fast and effective identification of the bioactive compounds and their targets from medicinal plants via computational chemical biology approach
Zhang, S., Lü, W., Liu, X., Diao, Y., Bai, F., Wang, L., Shan, L., Huang, J. Y., Li, H., & Zhang, W. (2011) · MedChemComm · doi:10.1039/c0md00245c · Cited by 37
NMR and Alanine Scan Studies of Glucose-dependent Insulinotropic Polypeptide in Water
Alaña, I., Parker, J. C., Gault, V. A., Flatt, P. R., O'Harte, F. P. M., Malthouse, J. P. G., & Hewage, C. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510414200 · Cited by 37
Obesity: the hormonal milieu
Lenz, A., & Diamond, F. (2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282f43a5b · Cited by 39
Effects of Non-Glycated and Glycated Glucagon-Like Peptide-1(7-36) Amide on Glucose Metabolism in Isolated Mouse Abdominal Muscle
O'Harte, F. P. M., Gray, A. M., Abdel‐Wahab, Y. H. A., & Flatt, P. R. (1997) · Peptides · doi:10.1016/s0196-9781(97)00201-5 · Cited by 37
The Long Road to the Development of Effective Therapies for the Short Gut Syndrome: A Personal Perspective
Jeppesen, P. B. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05779-0 · Cited by 36
Carbohydrate and Satiety
Feinle, C., O’Donovan, D., & Horowitz, M. (2002) · Nutrition Reviews · doi:10.1301/002966402320243241 · Cited by 36
Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action.
Ionut, V., Liberty, I. F., Hucking, K., Lottati, M., Stefanovski, D., Zheng, D., & Bergman, R. (2006) · American Journal of Physiology. Endocrinology and Metabolism · doi:10.1152/ajpendo.00106.2005 · Cited by 36
On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus.
Vilsbøll, T. (2004) · PubMed · Cited by 36
Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers
Chae, S. Y., Chun, Y. G., Lee, S., Jin, C., Lee, E. S., Lee, K. C., & Youn, Y. S. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21532 · Cited by 36
Chapter 19. DPP-IV inhibition and therapeutic potential
Villhauer, E. B., Coppola, G. M., & Hughes, T. E. (2001) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(01)36059-1 · Cited by 36
Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo
Green, B., Gault, V. A., Mooney, M., Irwin, N., Bailey, C. J., Harriott, P., Greer, B., Flatt, P. R., & O'Harte, F. P. M. (2003) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0310529 · Cited by 36

Authors: Kieffer, T. J., McIntosh, C. H., & Pederson, R. A.
Affiliations: University of British Columbia (CA)
ORCID: Kieffer, T J
Venue: Endocrinology
Publisher: The Endocrine Society
Published: 1995-08
Volume: 136
Issue: 8
Pages: 3585-3596
ISSN: 0013-7227 (ISSN-L)
1945-7170
DOI: 10.1210/endo.136.8.7628397
OpenAlex: W1978953702
Cited by: 1,124
References: 36
Citations by year: 2026: 9 · 2025: 31 · 2024: 30 · 2023: 15 · 2022: 27 · 2021: 36 · 2020: 23 · 2019: 37 · 2018: 25 · 2017: 40 · 2016: 39 · 2015: 54 · 2014: 47 · 2013: 53 · 2012: 61
FWCI: 6.60
Type: journal article
Language: en
Open access: closed
Locations: Endocrinology (publishedVersion)
PubMed (publishedVersion)
Funders: Massachusetts General Hospital
Novo Nordisk
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dipeptidyl peptidase IV, hormone degradation, incretin effect, N-terminal truncation, diprotin A, radiolabeled peptides, insulin secretion, circulating hormone levels
MeSH terms: Animals, Blood Physiological Phenomena, Glucagon-Like Peptides, Glucagon, Glucose, Peptide Fragments, Peptides, Protein Precursors, Rats, Inbred F344, Rats, Wistar, Dipeptidyl Peptidase 4, Rats, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks